Clinical Trial Update: Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients [Phase 2]

View source ↗

Summary

Phase 2 trial update comparing durvalumab and tremelimumab with gemcitabine or gemcitabine/cisplatin versus gemcitabine/cisplatin in cholangiocarcinoma and gall…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Gallbladder Carcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Durvalumab (durvalumab)
• Gemcitabine (Gemcitabine)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Cholangiocarcinoma, Gall Bladder Carcinoma | Phase 2 | Status: COMPLETED